Linked Life Data

17013989

Source:http://linkedlifedata.com/resource/pubmed/id/17013989

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2006-10-10
pubmed:abstractText
Virus-specific CD4+ T cells with IL-2-secreting and/or proliferative capacity are detected readily in HIV-1-infected long-term nonprogressors and rarely in persons with untreated progressive infection. The contribution of these cells to viraemia control is uncertain, but this question might be addressed in clinical therapeutic vaccination studies. However, the quality of T helper responses induced by currently available HIV-1 vaccine candidates has not been explored in depth. We determined the effect of vaccination with modified vaccinia virus Ankara (MVA) expressing HIV-1 gag p24/p17 (MVA.HIVA) on HIV-1-specific CD4+ T cell responses in 16 chronically infected, highly active antiretroviral therapy (HAART)-treated subjects using CD8-depleted IFN-gamma ELISPOT assays, intracellular cytokine staining assays for IL-2 and IFN-gamma, and a CFSE-based proliferation assay. Gag-specific CD4+ T cell responses were significantly increased in magnitude and breadth after vaccination and targeted both known and new epitopes, several of which were also recognised by healthy HIV-uninfected volunteers immunised with the same vaccines. The frequencies of CD4+ T cells expressing IL-2 or IFN-gamma, alone or simultaneously, were also augmented. These findings indicate that functional virus-specific T helper cells can be boosted by vaccination in chronic HIV-1 infection. Further evaluation of their role in viraemia control is warranted.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0014-2980
pubmed:author
pubmed:issnType
Print
pubmed:volume
36
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2585-94
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:17013989-AIDS Vaccines, pubmed-meshheading:17013989-Acquired Immunodeficiency Syndrome, pubmed-meshheading:17013989-Amino Acid Sequence, pubmed-meshheading:17013989-Antiretroviral Therapy, Highly Active, pubmed-meshheading:17013989-CD4-Positive T-Lymphocytes, pubmed-meshheading:17013989-Epitopes, T-Lymphocyte, pubmed-meshheading:17013989-Gene Products, gag, pubmed-meshheading:17013989-HIV Core Protein p24, pubmed-meshheading:17013989-HIV Infections, pubmed-meshheading:17013989-HIV-1, pubmed-meshheading:17013989-Humans, pubmed-meshheading:17013989-Interferon-gamma, pubmed-meshheading:17013989-Interleukin-2, pubmed-meshheading:17013989-Molecular Sequence Data, pubmed-meshheading:17013989-Peptide Fragments, pubmed-meshheading:17013989-Vaccines, DNA, pubmed-meshheading:17013989-Vaccinia virus, pubmed-meshheading:17013989-env Gene Products, Human Immunodeficiency Virus
pubmed:year
2006
pubmed:articleTitle
Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses.
pubmed:affiliation
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't